Janssen
DARZALEX FASPRO
Manufacturer:
Janssen
Name:
DARZALEX FASPRO
HCPCS Code Descriptor:
Injection, daratumumab, 10 mg and hyaluronidase-fihj
Category:
J Code
HCPCS:
J9144
NDC(s):
57894-0503-01
Primary Type:
Oncology
Generic Status:
Single-Source
Route of Administration:
Subcutaneous
About:
DARZALEX FASPRO is an Oncology drug manufactured by Janssen and administered via the Subcutaneous route of administration. The J Code: J9144 is aligned to the drug DARZALEX FASPRO.
Access Pricing and More By Registering
HCPCS Added Date:
1/1/21
HCPCS Effective Date:
1/1/21
HCPCS Short Description:
Daratumumab, hyaluronidase
Billing and Coding Guide:
https://www.janssencarepath.com/hcp/sites/www.janssencarepath-v2.com.hcp/files/darzalex-faspro-reimbursement-and-access-guide.pdf?v=128
Patient Assistance:
Not Found